RxDoctor Payments Data

Allen Mathew, MD

Nephrology · Eureka, CANPI 1417053075

Payments from drug & device makers

$5,379in general payments, 2019–2025

Across 54 payments — averaging $99.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Calliditas Therapeutics US Inc.$2K
  • Amgen$2K
  • Fresenius USA Marketing, Inc.$216
  • Lilly USA, LLC$196
  • Novo Nordisk$160
  • Mallinckrodt Hospital Products Inc.$143
  • plus $373 from 8 others

What the payments were for

  • Consulting fees$1,16022%
  • Travel & lodging$1,81334%
  • Food & beverage$2,27442%
  • Education$1322%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,379 in reported general payments places this provider in the 70th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$226,562
Medicare patients
125
Services billed
1,280

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide152$165,447
VelphoroSucroferric Oxyhydroxide27$85,408
EliquisApixaban55$64,097
TrulicityDulaglutide64$60,450
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$21,626
Sevelamer Carbonate78$17,253
VeltassaPatiromer Calcium Sorbitex15$13,730
Praluent PenAlirocumab17$13,171
Aripiprazole38$10,307
JardianceEmpagliflozin12$9,214
KerendiaFinerenone14$9,032
Clonidine41$7,398
Repatha SyringeEvolocumab23$6,135
Calcium Acetate57$5,725
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$4,733

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$196$225,897216 claims
Fresenius USA Marketing, Inc.Velphoro$216$85,40827 claims
BayerKerendia$14$9,03214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,341 nephrology providers in California.

Other nephrology in Eureka

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →